Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

Sanofi Pasteur Commends Winners of International BioGENEius Challenge

June 28, 2011 10:36 am | by Bio-Medicine.Org | News | Comments

SWIFTWATER, Pa., June 28, 2011 /- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY ), offers its congratulations to the four winners of the International BioGENEius Challenge, a competition for high school students who demonstrate an exemplary understanding of...

FDA Consumer Health Information - FDA's MedWatch Safety Alerts: May 2011

June 28, 2011 10:36 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., June 28, 2011 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has recently issued safety alerts about a number of products, including: (Logo: ) birth control pills that may increase the risk of blood...

New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients

June 28, 2011 10:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 28, 2011 /- Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart...


Aeris Therapeutics names new CFO Carter

June 28, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Aeris Therapeutics LLC, a Woburn-based drug developer focused on treatments for emphysema and other advanced lung diseases, has appointed a new chief financial officer in Charles R. Carter.

Patients Treated with Sunitinib and Sorafenib Respond to Flu Vaccine

June 28, 2011 9:34 am | by AACR | News | Comments

Tweet   • Flu vaccine could be used to test immune response. • Patients presented with metastatic renal cell cancer. • Implications beyond quality of life and patient management. PHILADELPHIA - Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests...

Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team

June 28, 2011 8:37 am | by Bio-Medicine.Org | News | Comments

MINNEAPOLIS, June 28, 2011 /- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and...

Hologic to Release Third Quarter Fiscal 2011 Operating Results on Monday, August 1, 2011

June 28, 2011 8:36 am | by Bio-Medicine.Org | News | Comments

BEDFORD, Mass., June 28, 2011 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced plans to...

Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform

June 28, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

RESTON, Va., June 28, 2011 /- The Mirixa Corporation and the Canadian Association of Chain Drug Stores (CACDS) are pleased to announce that MirixaPro(SM), a Web-based clinical platform that supports and documents standardized, pharmacy-based patient care service delivery, will be deployed...


Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men

June 28, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, June 28, 2011 /- Eli Lilly and Company (NYSE: LLY ) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution CIII, when applied to the underarm, met the primary study objective...

Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease

June 28, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

HOBOKEN, N.J., June 28, 2011 /- Octapharma USA recently hosted an International Physician Advisory Board in New York City, bringing together medical experts from around the world who have extensive experience internationally with taking care of patients with von Willebrand's Disease...

IBM Study Identifies New Generation of Connected Health Devices

June 28, 2011 7:37 am | by IBM | News | Comments

Consumers have a growing appetite for health and wellness devices, and this represents a burgeoning market opportunity for device manufacturers that has barely been tapped, according to a study from IBM (NYSE: IBM). The company also unveiled a list of possible wellness device innovations...

Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit

June 28, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

MADISON, Wis., June 28, 2011 /- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011, Judge Nathaniel M. Gorton allowed the defendants' motion to dismiss the putative federal...

Rcadia Medical Imaging Awarded Four U.S. Patents Covering Technology for Automated Analysis of Coronary CT Angiography

June 28, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

NEWTON, Mass., June 28, 2011 /- Rcadia Medical Imaging today announced that the company has been granted four patents by the U.S. Patent and Trademark Office covering technology for its COR Analyzer® System.  The COR Analyzer performs fully automatic analysis of Coronary CT...


DaTscanâ„¢ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes

June 28, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

PRINCETON, N.J., June 28, 2011 /- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with...

InfraReDx rounds up $24M in new funding

June 28, 2011 5:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Burlington-based medical device firm InfraReDx Inc. said it has raised $24.1 million in a new equity offering, seven months after completing a $21 million equity round.

Launch of Nuromol a New Painkiller Combination

June 28, 2011 2:33 am | by Bio-Medicine.Org | News | Comments

LONDON, June 28, 2011 /-   Stronger and Effective for Longer Versus Standard Paracetamol Tablets , as Shown in a Dental Pain Study [ 1] A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and...

Reportlinker Adds HIV Diagnostics Market in India

June 28, 2011 12:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, June 28, 2011 /- announces that a new market research report is available in its catalogue: HIV diagnostics market in India...

Boston Scientific Welcomes Passage of Patent Reform Bill

June 27, 2011 1:36 pm | by Boston Scientific | News | Comments

NATICK, Mass., June 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed approval by the U.S. House of Representatives of the America Invents Act of 2011.  The legislation, introduced by Rep. Lama

ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes

June 27, 2011 12:35 pm | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., June 27, 2011 /- ChemoCentryx, Inc. today announced that the Company's novel CCR2 antagonist significantly improves kidney function and hyperglycemia in experimental models.  These data implicate CCR2-driven processes in the pathology of type 2 diabetes and...

At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare

June 27, 2011 12:35 pm | by Bio-Medicine.Org | News | Comments

WASHINGTON, June 27, 2011 /PRNewswire-USNewswire/ -- Providers of durable medical equipment and services (DME) required in the home have called on President Obama to repeal Medicare's controversial "competitive" bidding for homecare, which cuts quality and access to care for seniors and...

China Grants COPAN Patent for Flocked Swabs

June 27, 2011 12:35 pm | by Bio-Medicine.Org | News | Comments

MURRIETA, Calif., June 27, 2011 /- COPAN announced this week that it has received the Chinese patent for its invention of flocked swabs, FLOQSwabs™, for collection and transfer of biological samples.  The Chinese flocked swabs patent is the latest addition to a growing number...

DePuy ASR Hip Resurfacing System Failure Leads to Lawsuit, According to the Law Offices of John David Hart

June 27, 2011 12:34 pm | by Bio-Medicine.Org | News | Comments

HOUSTON, June 27, 2011 /- Charlotte Mustard and her husband, Jeremy, filed suit today against DePuy Orthopaedics, Inc., DePuy Inc., DePuy International, Ltd., Johnson & Johnson, Inc., Johnson & Johnson Services, Inc. and Johnson & Johnson International, Inc., seeking...

Pepto-Bismol and Nick Cannon Heat Things up at this Year's Nathan's Famous Fourth of July International Hot Dog Eating Contest

June 27, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

CINCINNATI, June 27, 2011 /- Pepto-Bismol announced today that for the second year in a row, Independence Day is marked by red, white and … PINK? In an act of true gastro-patriotism, Pepto-Bismol has decided to be the stomach-remedy sponsor of the Nathan's Famous Fourth of July...

New Arrivals of Exercise & Health Care Equipment

June 27, 2011 11:32 am | by Bio-Medicine.Org | News | Comments

SHENZHEN, China, June 27, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International Trading Co., a leading online distributor specializing in health care electronics & medical equipment, announces its new arrivals of exercise equipment and health care electronics, which have...

EnVivo begins Phase 1 Alzheimer's drug trial

June 27, 2011 10:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

EnVivo Pharmaceuticals Inc. of Watertown, which focuses on central nervous system therapies, said it has started a Phase 1 trial of its EVP-0962 Alzheimer's drug candidate in healthy volunteers.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.